Physician profile
Gilbert Emde
NPI 1801889373
$1,892.28
in general payments reported to CMS, 2019-2025
23 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $52.70 · 2021: $319 · 2022: $210 · 2023: $115 · 2024: $314 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.15 |
| Education | $124.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $414.97 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $402.46 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $174.38 | 2019-2025 | Breztri |
| Amarin Pharma, INC. | $144.86 | 2019-2021 | |
| Pfizer INC. | $131.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $103.77 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Madrigal Pharmaceuticals | $79.33 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.69 | 2019-2021 | |
| Lilly USA, LLC | $59.98 | 2019-2025 | Zepbound |
| Amgen INC. | $52.11 | 2019-2021 | |
| Abbvie INC. | $34.52 | 2023 | |
| Dexcom, INC. | $29.63 | 2022-2023 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $29.48 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $26.90 | 2024 | Lumryz |
| Janssen Pharmaceuticals, INC | $24.22 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $23.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.99 | 2022 | |
| Merck Sharp & Dohme LLC | $15.74 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $14.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.61 | 2022 | |
| Novo Nordisk INC | $13.40 | 2019 | |
| Abbott Laboratories | $12.60 | 2022 | |
| Hologic Sales and Service, LLC | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Emde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.